Bayer’s experimental stroke drug could reshape secondary stroke prevention
Millions of stroke survivors across the world may soon have a new defense
Millions of stroke survivors across the world may soon have a new defense
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction
According to the ICMR-INDIAB study, 11.4% of adults in India have type 2 diabetes, while a staggering 15.3% are pre-diabetic
The X CUBE 50 integrates ALPINION’s advanced X+ Architecture
The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
The move is expected to be crucial during health crises
Over 700 exhibitors from APAC, Europe, the US, and beyond showcased the latest in personal care innovation
Subscribe To Our Newsletter & Stay Updated